منع الإخصاب .. للدكتور مرس .. أطفال تحت الطلب ومنع الحمل

Prevent fertilization

By Dr. Mors
This research was presented at the 2nd European Fertilization Society meeting

In Britain, there is a special council to investigate contraindications to fertilization, and its mission is to encourage and conduct research in this field. The Council makes the necessary arrangements for clinical research on new anti-fertility treatments. Most of the work he has done so far has dealt with the latest progestogens or estrogen compounds to stop ovarian activity.

Eugenon was presented to the Council and studies were conducted on it for the first time by Dr. Swire to determine the extent of its ability to suppress ovarian activity and postpone menstruation and the extent to which humans tolerate it. Then this compound was studied in our central clinic, and this compound may be considered an inhibitor of ovarian surgery in itself. It was also studied and tested adequately in a number of women in several other places.
So far, large-scale experiments have been conducted in nine clinics that used different types of this compound on one thousand two hundred women who completed more than ten types of seven thousand cycles.
It is the Council's job to approve a compound for use in Family Planning Association clinics, and manufacturers typically do not market products unless they have approved it as such. So far, the Council has approved four oral contraceptives: Metroline, Metrolen, and Eugynon. The fourth is Volidan, which is the most recent.
It is evident from the studies conducted on the first three that no pregnancy incidents occurred due to a defect in the pills. It has been observed that pregnancy does not occur with these preparations, even though some women failed to take several tablets. It has been shown from numbers and statistics that these preparations are more acceptable than other preparations. It was tried on 196 women who completed 2,093 cycles, and pregnancy did not occur in any case, neither because of missing the pills nor because of the women’s failure to follow the instructions carefully.

It is our custom, after the initial testing and when the treatment reaches the stage of large-scale confidential testing, to consider having one hundred women use this treatment for six months as sufficient to compare it with other treatments.

On this basis, we tested the three compounds and found that there was only a very small difference in the final results for the first six months.
For women who took Conovit, it was found that there was some decrease in Amenorrhea incidents and breast pain, with an increase in the number of women withdrawing from the trial.

As for Conovid H, there was a decrease in Amenorrhea incidents, an increase in the number of women with reduced flow, and an increase in the number of those withdrawing from the trial. As for Eugenon, there was a decrease in breast pain, some increase in amenorrhea incidents, and a noticeable decrease in the amount of flow.
There is, of course, a minimum dose at which these products are no longer useful. There appears to be a dose of maximum benefit for each compound above the minimum dose with regard to menstrual control and the rate of side effects, which may vary significantly. There is little difference in incidents of nausea because the amounts and percentages of estrogen are different to this extent.
It is worth noting that the dose with maximum benefit for European women is not the same as the dose with maximum benefit for other races. Van Conovid e. For example, an excellent tablet in Ceylon. It should also be noted that there is | A wider range of maximum beneficial doses in some products compared to other products.

It is important, when listing the experiments conducted, to point out the negative results:
1- There were no cases of virilization in any of the women participating in these experiments.

2 - The women who withdrew from the experiment in order to try to become pregnant did not encounter any difficulty. Forty-four women withdrew for this purpose, and thirty-nine of them became pregnant. Thirty-two became pregnant within three months, and the rest became pregnant within six months.

4 - The women who withdrew from treatment experienced only a slight delay in returning to the normal cycle. The formation of the egg and the first menstruation were sometimes delayed by a few days, not exceeding a maximum of ten days, and after that everything became normal.

5- Only four cases of Thromboplebitis occurred among the one thousand and two hundred women who were under the experiment. The normal incidence among non-pregnant women in this age group in Britain is 6 to 7 per thousand. This means that these cases fall within the normal limit.